Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Rev Cancer. Author manuscript; available in PMC 2010 March 1.
Published in final edited form as:
PMCID: PMC2829848

Cancer prevention by tea: animal studies, molecular mechanisms and human relevance


Extracts of tea, especially green tea, and tea polyphenols have been shown to inhibit the formation and development of tumours at different organ sites in animal models. There is considerable evidence that tea polyphenols, in particular (−)-epigallocatechin-3-gallate, inhibit enzyme activities and signal transduction pathways, resulting in the suppression of cell proliferation and enhancement of apoptosis, as well as the inhibition of cell invasion, angiogenesis and metastasis. Here, we review these biological activities and existing data relating tea consumption to human cancer risk in an attempt to understand the potential use of tea for cancer prevention.

Dietary factors can substantially influence human cancer risk. Many food items, beverages and dietary constituents have reported cancer-preventive or anticancer activities. Tea, a commonly consumed beverage derived from the dried leaves of the Camellia sinensis plant, has been studied extensively for its health benefits, including cancer prevention. These studies are important because tea is consumed by a large proportion of the world's population and is the most popular beverage after water. Therefore, tea is the major source of dietary flavonoids (or polyphenols) in many populations. Tea is a unique food item in that the major constituents, especially those in green tea, are well characterized, allowing their biological activities to be thoroughly studied. The relationship between tea consumption and human cancer can be investigated using retrospective and prospective studies in which tea consumption is assessed by dietary recalls or by specific urinary markers.

Although different aspects of tea and cancer prevention have been covered by previous reviews110, this Review critically assesses existing data and discusses our current understanding of how tea constituents might prevent cancer. We use selected recent findings to illustrate the types of laboratory results that are available. We also briefly review the results of human epidemiological and intervention studies, interpret these results on the basis of our understanding of the biochemical properties of tea constituents (BOX 1) and discuss possible mechanisms by which tea polyphenols prevent cancer development. Finally, we discuss the opportunities and challenges presented by the study of tea for cancer prevention. We hope that this Review will have wide-ranging implications, as many of the issues discussed here might also be applicable to studies of other dietary materials.

Box 1Constituents in green and black tea

Originating in China and South East Asia, tea plants have been cultivated for thousands of years. The leaves were initially used for medicinal purposes and only later as a popular beverage. Cultivated in more than 30 countries, ~3.8 million tonnes of tea are produced annually. The composition of tea varies with climate, horticultural practices, variety and the age of the leaves. The different production methods alter the chemical composition of the dried tea leaves. Green tea, which accounts for 20% of world tea consumption, is prepared by pan-frying or steaming and then drying the tea leaves to inactivate polyphenol oxidase and other enzymes. These processes preserve the characteristic tea polyphenols known as catechins, which account for 10–15% of the weight of the dried leaves. The major catechins are (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG) and (−)-epicatechin (see the figure). EGCG is the most abundant catechin, and may account for 50–75% of the catechins. Catechin, catechin gallate, gallocatechin, gallocatechin gallate, epigallocatechin digallates, epicatechin digallate, methylepicatechin and methyl EGC are present in smaller quantities. Flavonols, including quercetin, kaempferol, myricetin, and their glycosides, are also present in tea. A typical cup of green tea, brewed with 2.5 g of tea leaves in 250 ml of hot water, contains 620–880 mg of water-extractable materials of which about one-third are catechins and 3–6% is caffeine.

Black tea, which accounts for 78% of world tea consumption, is prepared by crushing the tea leaves and causing enzyme-catalysed oxidation and polymerization of tea catechins in a process commonly known as fermentation. This process results in the formation of oligomers, such as theaflavins (see the figure) and polymers known as thearubigins, which account for 2–6% and 15–20%, respectively, of the dry weight of the black tea infusion. Theaflavins are characterized by the benzotropolone ring structure and a bright red or orange colour, and contribute to the unique taste of black tea. Thearubigins, which have higher molecular weights, are poorly characterized chemically and biochemically. Oolong tea, which accounts for 2% of world tea consumption, is made by a delicate procedure that crushes only the rim of the tea leaf in a short fermentation process. The product retains higher levels of catechins and contains newly formed oligomers of catechins, such as theasinensins.

An external file that holds a picture, illustration, etc.
Object name is nihms146308f2.jpg

Tea constituents and their biochemical properties

The major catechins (a group of polyphenols) in green tea are (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG) and (−)-epicatechin (BOX 1). Tea catechins are characterized by the dihydroxyl or trihydroxyl substitutions on the B ring and the m-5,7-dihydroxyl substitutions on the A ring11. The B ring seems to be the principal site of antioxidant reactions12,13 and the antioxidant activity is further increased by the trihydroxyl structure in the D ring (gallate) in EGCG and ECG. The polyphenolic structure allows electron deloalization, conferring the ability to quench free radicals. Tea preparations have been shown to react with reactive oxygen species (ROS) such as superoxide radical, singlet oxygen, hydroxyl radical, peroxyl radical, nitric oxide, nitrogen dioxide and peroxynitrite1113. Among tea catechins, EGCG is the most effective in reacting with the majority of ROS. Tea polyphenols are also strong chelators of metal ions; the chelation of free metal ions prevents the formation of ROS from the auto-oxidation of many compounds.

The vicinal dihydroxy or trihydroxy structures not only contribute to the antioxidative activity of tea polyphenols, but also increase the susceptibility of these compounds to air oxidation under alkaline or neutral pH. In the case of EGCG, auto-oxidation generates superoxide anion and hydrogen peroxide and leads to the formation of dimers, such as theasinensins14. These reactions occur under cell culture conditions, and we propose that this is due to superoxide anion-catalysed chain reactions because EGCG can be stabilized by the addition of superoxide dismutase (SOD).

At a glance

  • Tea, made from the dried leaves of the plant Camellia sinensis, is the most popular beverage worldwide after water.
  • Tea and tea polyphenols have been shown to inhibit tumour formation and growth in different animal models for human cancer. The inhibition is associated with decreased cell proliferation, increased apoptosis and suppression of angiogenesis.
  • Tea polyphenols are antioxidants, but they can also generate reactive oxygen species. The major polyphenol from green tea, (−)-epigallocatechin-3-gallate, has been shown to bind directly to several receptors and signalling molecules, and to inhibit the functions of key receptors, kinases, proteinases and other enzymes.
  • Epidemiological studies, however, have not yielded conclusive results on the cancer-preventive effect of tea consumption in humans, possibly owing to different confounding factors. Some human cancer prevention trials with green tea polyphenol preparations have shown promising results.
  • Well-designed epidemiological studies and intervention trials are needed to evaluate the cancer-preventive activities of tea and tea polyphenols in humans.
  • Many issues raised and the experience gained from studies on tea and cancer prevention maybe applicable to studies on other dietary constituents.

The polyphenolic structure of tea polyphenols also makes them good donors for hydrogen bonding. For example, hydrogen bonding of water molecules to EGCG forms a large hydration shell, which reduces the absorption of EGCG15 (BOX 2). This hydrogen bonding capacity also enables tea polyphenols to bind strongly to proteins and nucleic acids (discussed below). How these effects contribute to the cancer-preventive effect of green tea is partly determined by the bioavailability of these compounds in vivo1621 (BOX 2).

Box 2Absorption and metabolism of tea polyphenols

After drinking tea only a certain percentage of the polyphenols is absorbed, with those appearing in the blood and tissues considered bioavailable. The bioavailabilities of tea polyphenols with large molecular masses, such as theaflavins (564–868 Da), are low. (−)-Epigallocatechin-3-gallate (EGCG;458 Da) also has limited bioavailability and the smaller molecules, (−)-epigallocatechin (EGC) and (−)-epicatechin (306 Da and 290 Da, respectively), have higher bioavailabilities. For example, after drinking an equivalent of two cups of green tea, it takes 1.5–2.0 hours for the catechins to reach peak values in the blood, and the peak plasma levels for EGCG, EGC and (−)-epicatechin are 0.26,0.48 and 0.19 μM, respectively, although the EGCG content in tea is much higher than those of EGC and (−)-epicatechin. EGCG clears from the blood with an elimination half-life of 2.0–3.5 hours. The detailed pharmacokinetics of tea catechins in humans and rodents have been studied1620. The blood levels of EGCG in humans due to tea consumption or in animals receiving tea preparations in cancer prevention studies are generally lower than 0.5 μM. When large pharmacological doses of polyphenols are orally administered, peak plasma concentrations of 5–7 μM are observed in humans and mice. EGCG is excreted mainly through the bile to the faeces, with little excreted through the urine, whereas the smaller molecule EGC is excreted to the urine. Therefore, the urinary EGC and related metabolites can be used as an exposure marker for tea consumption.

Inside the body, tea polyphenols are readily methylated by S-adenosyl-methionine, which is catalysed by the enzyme catechol-O-methylthransferase (COMT). They are also catalysed by UDP-glucuronoryltransferase (UGT) and sulphotransferase (SULT) to form corresponding glucuronide and sulphate conjugates of catechins21. In addition, ring–fission metabolites, such as 5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone (M4), and 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone, are formed. These metabolites are produced by intestinal microflora, as humans and mice do not have the enzymes to catalyse the fission of the C ring and the hydrolysis of the ester bond in EGCG. These pathways are illustrated in the figure, using EGCG as an example. All these metabolites have biological activities, but the activities were lower than that of EGCG in cancer cell growth inhibition assays in vitro.

An external file that holds a picture, illustration, etc.
Object name is nihms146308f3.jpg

Inhibition of tumorigenesis in animal models

Cancer prevention by tea and tea components has been studied in many different animal models of carcinogenesis (reviewed in REFS 3,10) (TABLE 1). In a review of the 147 papers published up to December 2008, 133 described cancer-preventive or inhibitory effects; we briefly discuss some of these effects below.

Table 1
Inhibitory effects of tea and tea constituents in animal models*

Inhibition of lung tumorigenesis

Administration of green tea, black tea, green tea polyphenols, EGCG or theaflavins during the initiation or promotion stage of tumorigenesis inhibited 4-(N-methyl-N-nitrosamino)-l-(3-pyridyl)-l-butanone(NNK)-induced lung tumorigenesis in rats, mice and hamsters2230 (BOX 3). In a recent study, A/J mice were treated with a single dose of NNK and kept for 20 weeks to allow lung adenomas to develop. Mice were then given 0.5% polyphenon E (PPE), or 0.044% caffeine, in their drinking fluid for 32 weeks; this treatment reduced the progression of lung adenomas to adenocarcinomas30. PPE or caffeine treatment was shown to inhibit cell proliferation, increase apoptosis and decrease levels of the phosphorylated transcription factors TUN, ERK1 and ERK2 in adenocarcinomas. However, in normal lung tissue, neither agent had any significant effect on the levels of cell proliferation or apoptosis. Treatment of A/J mice with green or black tea for 60 weeks also inhibited the spontaneous formation of lung tumours31. In a metastasis model, oral administration of green tea infusion reduced the number of murine Lewis lung carcinoma cell colonies32. These results suggest that tea preparations exert an inhibitory effect at all stages of lung carcinogenesis. However, high doses of tea polyphenols are required to produce a cancer-preventive effect, possibly owing to the relatively low bioavailability of EGCG.

Box 3A lung tumorigenesis model in A/J mice

Tobacco carcinogens 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a]P) are commonly used to induce lung cancer in mice2228. A/J mice have been used extensively in these studies because they are prone to the development of lung tumours. The following figure illustrates that after treatment (intraperitoneal injection) of the mice with one dose of NNK, lung tumours develop in almost all the mice in 16–20 weeks. Inhibition of tumorigenesis has been demonstrated when tea preparations are administered to the mice in drinking water for 3 weeks, starting 2 weeks before the NNK treatment22. NNK is metabolically activated to electrophiles that alkylate DNA, and mutational activation of the Ras oncogenes is a key step in the initiation of tumorigenesis. In the second version of this model, tea preparations are administered 1 week after the NNK treatment until the termination of the experiment. Inhibition of tumorigenesis has also been observed22. The action of tea preparations in this case is considered to be exerted during the post-initiation stage. In the third version, the mice are kept for 16–20 weeks to allow tumours to develop, and they are then treated with tea preparations for another 30–40 weeks to allow the tumours to progress to adenocarcinoma. This is considered a progression model and the inhibitory effect of tea preparations has also been demonstrated30. B[a]P or a combination of B[a]P and NNK has also been used to induce lung tumours in the A/J mice34. Multiple lower doses of these carcinogens administered in longer treatment periods have been used by some researchers23.

An external file that holds a picture, illustration, etc.
Object name is nihms146308f4.jpg

A new approach for cancer prevention is the use of polyphenols in combination with other agents. For example, we recently demonstrated the synergistic inhibitory action of a combination of PPE and the lipid-lowering agent atorvastatin against NNK-induced lung carcinogenesis in A/J mice33. The synergistic action of this combination was also demonstrated in human lung cancer H1299 and H460 cells. In both the cell lines and the mouse model, downregulation of the anti-apoptotic proteins MCL1 and BCL-XL and induction of apoptosis were associated with the synergistic inhibitory action33. The possible synergistic actions between atorvastatin and tea in humans warrant future investigation.

Lu et al.34 recently analysed the gene expression changes caused by the administration of green tea or PPE in the inhibition of NNK- or benzo[a]pyrene (B[a]P)-induced lung tumorigenesis in A/J mice. The authors found that the differential expression of 88 genes in tumours compared with normal tissues was reversed by green tea or PPE treatment. These authors also identified a classifier of 17 genes that was altered by tea and PPE treatments in both normal lungs and lung adenomas; they suggested that these genes could be used as markers for tea exposure. Additional studies are needed to verify the results and relate these gene expression changes to protein levels.

Inhibition of oral-digestive tract tumorigenesis

The cancer-preventive activities of tea and tea constituents have also been studied in different models of oral–digestive tract carcinogenesis (reviewed in REF. 10). Tea preparations have been shown to inhibit chemically induced oral carcinogenesis in a hamster model and oesophageal carcinogenesis in a rat model35,36, as well as tumorigenesis in rat stomach and forestomach induced by N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)37. A recent study showed that 0.05% black tea polyphenols (polyphenon B) given through the diet effectively inhibited tumour formation in a similar model38; this inhibition was associated with reduced cell proliferation, infiltration and angiogenesis, as well as increased apoptosis.

In the ApcMin/+ mouse model of intestinal tumorigenesis, EGCG solution (0.02–0.32%, weight:volume), given as the sole source of drinking fluid, inhibited the spontaneous development of small intestinal tumours in a dose-dependent manner39. Inhibition of tumour multiplicity was associated with increased expression of the cell signalling protein epithelial cadherin (E cadherin) and decreased levels of nuclear β-catenin, MYC, phospho-Akt, phospho-ERK1 and phospho-ERK2. Caffeine was not effective in inhibiting tumorigenesis in this animal model. We also compared the efficacy of EGCG as a pure compound with a defined catechin mixture, PPE, in the ApcMin/+ mouse model40. Total tumour multiplicity was decreased by both dietary PPE (0.12%) and the corresponding amount of dietary EGCG (0.08%). Although PPE seemed to be more effective than EGCG, the difference was not statistically significant. Additional studies are required to further elucidate whether PPE or other green tea catechin preparations are more effective at inhibiting tumorigenesis than EGCG.

A review of the literature indicates that the colon cancer prevention activity of tea and tea polyphenol preparations has been consistently demonstrated in mouse models, but results from studies in rat models have been inconsistent (reviewed in REF. 10). We recently examined the effect of PPE on the development of aberrant crypt foci (ACF) and adenocarcinoma in the colons of rats treated with azoxymethane. The treatment of rats with PPE (0.24% in the diet) for 8 weeks decreased the total number of ACF per rat by 36.9%. In ACF with high-grade dysplasia the inhibitory activity of PPE was associated with decreased levels of nuclear β-catenin and cyclin D1, and increased retinoid X receptor-α staining41. Treatment with 0.24% PPE for 34 weeks decreased the incidence of adenocarcinoma by 60% and the multiplicity of adenocarcinoma and adenoma by 80% and 45%, respectively (C.S.Y. et. al, unpublished observations). In a model using a food carcinogen, PhIP (2-amino-l-methyl-6-phenylim-idazo[4,5-6]pyridine), to induce colon carcinogenesis in rats, treatment with EGCG during the post-initiation stage for 15 weeks reduced ACF formation by 71% compared with water-treated controls42. Conversely, in rats given PhIP and a high-fat diet, subsequent administration of tea (2%) or caffeine (0.065%) in drinking water, in the post-initiation stage, significantly increased colon tumour incidence43. This suggests that caffeine can promote colon tumorigenesis under these experimental conditions.

Inhibition of prostate tumorigenesis

Liao et al. have demonstrated the growth-inhibitory activity of EGCG when administered by intraperitoneal injection to mice with human prostate cancer xenografts44. Mukhtar et al. have also shown that administration of a green tea polyphenol infusion (0.1% in drinking fluid) to transgenic adenocarcinoma of the mouse prostate (TRAMP) mice for 24 weeks markedly inhibits prostate cancer development and distant site metastases45,46. In the mice receiving tea polyphenols cell proliferation was decreased and apoptosis was increased, insulin-like growth factor 1 (IGF1) level was decreased, and IGF binding protein 3 (IGFBP3) was restored to normal levels in both serum and the dorso-lateral prostate45,46. This modulation of IGF1 and IGFBP3 levels was associated with reduced levels of phosphotidylinositol 3-kinase (PI3K), and of the phosphorylated forms of Akt, ERK1 and ERK2. The green tea polyphenol treatment also significantly decreased levels of angiogenic and metastatic markers, such as vascular endothelial growth factor A (VEGFA), matrix metalloproteinase 2 (MMP2) and MMP9. These results suggest that the inhibition of VEGFA, MMPs and the IGF1 signalling pathway contributes to the cancer prevention activity of green tea polyphenols.

Possible cancer prevention by tea in humans

The effects of tea consumption on the risk of human cancer have been investigated in many epidemiological studies, but the results have been inconclusive (reviewed in REF 10). A literature search in the PubMed database for papers published up to December 2008 showed 127 case–control studies and 90 cohort studies on the relationship between tea consumption and the risk for colon, lung, stomach, breast, prostate, ovarian, pancreatic, kidney, bladder and other cancers (TABLE 2). Of these studies, only 51 case–control studies and 19 cohort studies showed an inverse association between tea consumption and cancer risk, suggesting a cancer-preventive effect of tea, whereas other studies showed no such association. One overall impression is that the cancer-preventive effect is seen more frequently in case–control studies than in prospective cohort studies. Cancer risk reduction is also observed more frequently in studies on green tea than in those on black tea, which is probably because many polyphenols in black tea are poorly, or not, bioavailable (BOX 2).

Table 2
Studies on tea consumption and the risk of human cancer*

Confounding and modulating factors

The inconsistent results of the epidemiological studies were probably due to different confounding factors, difficulties in quantifying tea consumption, varied cancer aetiology in different populations and population heterogeneity. When these factors were effectively managed, a clearer relationship between tea consumption and cancer risk was observed in several studies; some examples are discussed below.

Cigarette smoking and alcohol consumption are important interfering factors. For example, in a case–control study on oesophageal cancer in Shanghai by Gao et al.47, a protective effect of green tea consumption was observed in women, mostly non-smokers, with an odds ratio (OR) of 0.50 and a 90% confidence interval (CI) of 0.30–0.83. However, no protective effect was found in men, who were mostly smokers. In a subset of subjects who neither smoked tobacco nor drank alcohol, oesophageal cancer risk among tea drinkers was significantly decreased in both men (OR = 0.43; 95% CI = 0.22–0.86) and women (OR = 0.40; 95% CI = 0.20–0.77). In Asia, tea drinking is commonly associated with cigarette smoking in men. Although many studies tried to correct for smoking, the interaction between these two factors is difficult to assess.

The quantity and quality of the tea consumed affects the outcome of epidemiological studies. The lack of a preventive effect of tea consumption against cancer formation observed in many studies may be due to the low quantity of tea consumed. In some studies in Japan, daily consumption of ten cups of tea was required for the cancer-preventive effect48. In the study by Gao et al.47, the quantity of green tea consumption was reported as grams of dry tea leaves consumed, and they found a protective effect against oesophageal cancer in women who consumed ≥150 g of tea per month (an equivalent of 2–3 cups of tea per day). Similarly, in a case–control study in nearby Zhejiang province, consumption of ≥250 g of dried green tea leaves per annum was associated with a reduced risk for breast cancer49. As the habit of tea drinking in these areas is known, reporting grams of tea consumed may be a good way of assessing tea consumption. Objective measurements of biomarkers that reflect exposure to tea, such as urinary catechins and their metabolites50,51, may also be useful. For example, in a nested case–control study in the Shanghai cohort, we used the presence of urinary EGC as an indicator of tea consumption and found that it was inversely associated with gastric cancer risk50. The protective effect was primarily observed in subjects with lower levels of serum carotenoids, suggestive of an antioxidative mechanism for the action of green tea50. In a similar study in this Shanghai cohort, urinary EGC (or EGC plus its metabolite, 4′-methyl-EGC) was inversely associated with colon cancer risk51. In a recent nested case-control study in a large population-based prospective study in Japan, plasma levels of ECG were associated with a decreased risk of gastric cancer in women, but not in men52. Once again, it is plausible that these results reflect a higher proportion of smokers in the male population compared with the female population52.

Genetic polymorphism in the population may also affect the relationship between tea consumption and cancer risk. For example, a population-based case–control study of women of Asian descent living in Los Angeles, United States, found a significantly reduced risk of breast cancer among green tea drinkers who carried at least one low-activity allele of catechol O-methyltransferase53,54. Individuals with low-activity alleles of this enzyme may have prolonged exposure to catechins and their cancer-preventive functions. Effects of genetic polymorphism on lung cancer prevention by tea have also been reported55.

Intervention studies

Well-designed intervention studies may provide aclear demonstration of the cancer-preventive effects of tea preparations. Early studies have shown the chemopreventive effects of tea in human oral precancerous mucosa lesions56 and human cervical lesions57. In a recent double-blinded study in Italy, 30 men with high-grade prostate intraepithelial neoplasia (PIN) were given 600 mg of green tea catechins daily for 12 months. Only 1 patient developed prostate cancer, whereas 9 of the 30 patients with high-grade PIN in the placebo group developed prostate cancer58. These results are promising and would have a large impact if they could be reproduced in similar trials with larger numbers of subjects. In a recent study in Japan, supplementation of green tea extract (1.5 g per day for 12 months) in patients who had colorectal adenomas removed by polypectomy was shown to reduce the development of metachronous colorectal adenomas compared with a group of patients who did not take green tea extract59. These patients are regular tea drinkers (average of 6 cups per day); the dose-response result of this study is difficult to explain and further studies are needed. The human trials cited above are all pilot studies; additional studies with larger numbers of patients for a longer duration are required to obtain more explicit information. More than 20 human trials with tea polyphenol preparations are ongoing or are planned (see clinical trials website in Further information); hopefully these studies will yield clear, consistent conclusions.

Mechanisms for cancer prevention by tea

Polyphenols, especially EGCG, have received most of the attention in studies of active tea constituents that can inhibit carcinogenesis, although the inhibitory activity of caffeine has also been demonstrated in lung and skin carcinogenesis models23,30,60. The mechanisms of action of caffeine in skin carcinogenesis models have been previously discussed by Conney et al.60 and so are not addressed here. This section discusses cancer-preventive mechanisms of the major tea polyphenol, EGCG.

Many mechanisms have been proposed based on studies with EGCG in cell lines. However, the concentrations of EGCG used in some of the cell culture experiments (20–100 μM) are higher than the plasma and tissue concentrations observed in humans after drinking two or three cups of green tea or in mice in cancer prevention experiments (usually <0.5 μM)21. It remains unclear whether the information obtained from cell lines with high EGCG concentrations can be extrapolated to cancer prevention in animals. In addition, many proposed mechanisms that are based on cell line studies are likely to be more relevant to therapeutic activity, rather than the cancer-preventive effect of tea.

As a chemical, EGCG can exert its actions by serving as an antioxidant or a pro-oxidant. It can also bind to target molecules and trigger cascades of signalling or metabolic pathways that lead to the inhibition of carcinogenesis. An assessment of our current understanding of the cancer prevention mechanisms is given below.

Antioxidation, pro-oxidation and carcinogen elimination

Although tea polyphenols are strong antioxidants in vitro, their antioxidative effects in vivo can only be demonstrated in certain studies. The bioavailability of tea polyphenols apparently limits the biological activity in vivo. Administering EGCG to old rats reduced oxidative stress, and the EGCG-treated animals had decreased levels of lipid peroxidation and protein carbonylation, as well as increased levels of antioxidants and antioxidant enzymes in the liver, skeletal muscle and brain61,62. However, no effects were observed in young rats, suggesting that the antioxidative effects of EGCG are only apparent in the presence of excessive oxidative stress. Similar conclusions have also been drawn from other studies in both animals and humans (reviewed in REF. 63). Supplementation of the diets of healthy human volunteers with tea catechins (500 mg per day) for 4 weeks resulted in an 18% decrease in plasma oxidized low-density lipoprotein compared with the control64. Similarly, supplementation of the diets of patients on haemodialysis with green tea catechins (455 mg per day) for 3 months decreased plasma hydrogen peroxide, C-reactive protein and several pro-inflammatory cytokines compared with placebo-treated controls65. The antioxidative activity of tea polyphenols could decrease oxidative DNA damage, and this has been shown in human and animal models. For example, in a randomized intervention study, supplementation of the diets of heavy smokers with 4 cups of decaffeinated green tea (73.5 mg of catechins per cup) for 4 months was found to reduce urinary 8-hydroxydeoxy-2′-deoxyguanosine (8-OHdG) levels by 31% compared with the control group66. Similarly, administration of green tea to smokers for 4 weeks reduced the number of 8-OHdG-positive cells to 50% of the pretreatment level67. As endogenously formed ROS are also important in promoting carcinogenesis, tea polyphenols may have important roles in quenching these species at different stages of carcinogenesis.

Conversely, tea catechins can also be oxidized to generate ROS, which are readily observed in cell culture medium, and lead to cell death14,68. After entering the cells, EGCG may also produce ROS by an unknown mechanism and the role of these ROS in cancer prevention is under investigation in our laboratory. ROS may also activate the nuclear factor erythroid 2-related factor 2 (NRF2, also known as NFE2L2) antioxidant-responsive element pathway to activate antioxidant and detoxifying enzymes69. This activation appears to occur in vivo: oral gavage of EGCG (200 mg per kg) to C57B1/6J mice upregulated gene expression of γ-glutamyltransferase, glutamate cysteine ligase and haemoxygenase 1 in the liver and colon70. Similarly, treatment of human volunteers for 4 weeks with 800 mg PPE per day increased glutathione S-transferase P activity in blood lymphocytes71. This effect was greatest in individuals with the lowest tertile baseline glutathione S-transferase P activity (80% increase compared with the baseline). Correspondingly, in a recent intervention study in a high aflatoxin exposure area in China, a 3-month supplementation with 500 or 1,000 mg green tea polyphenols per day increased the median urinary aflatoxin B1-mercapturic acid levels by more than tenfold compared with the baseline72. Conversely, there have been case reports showing that excessive amounts of tea extracts (taken as a dietary supplement for the purpose of weight reduction) induce liver toxicity73, which is probably caused by a pro-oxidant mechanism74. It remains to be determined whether the activation of NRF2 by ROS overlaps with the toxic effect of tea polyphenols.

Binding to molecular targets

The eight phenolic groups of EGCG can serve as hydrogen bond donors to many biomolecules. Previously, EGCG has been shown to bind to salivary proline-rich proteins, fibronectin, fibrinogen and histidine-rich glycoproteins, and more recently to proteins such as the 67 kDa laminin receptor75,76 and Bcl-2 proteins77 (FIG. 1).

Figure 1
Possible targets for the cancer preventive activity of (−)-epigallocatechin -3-gallate (EGCG)

Binding of EGCG to the 67 kDa laminin receptor with a dissociation constant (Kd) value of 0.04 μM was observed using a surface plasmon resonance assay75. Expression of the metastases-associated 67 kDa laminin receptor increased the responsiveness of MCF-7 cells to low micromolar concentrations of EGCG75. A recent study that used NMR spectroscopy showed the direct binding of tea polyphenols to the BH3 pocket of anti-apoptotic Bcl-2 proteins — inhibition constant (Ki) = 0.33–0.49 μM77. However, higher EGCG concentrations were needed to induce apoptosis.

Using an EGCG–Sepharose 4B column, two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight mass spectroscopy, Dong et al. identified vimentin78, insulin-like growth factor 1 receptor (IGF1R)79, FYN80, glucose-regulated protein 78 kDa (GRP78)81 and ZAP7082 as high-affinity EGCG binding proteins. All of these proteins were demonstrated to be important for the inhibitory activity of EGCG in cell lines, but higher EGCG concentrations than the Kd values were needed. For example, vimentin binds to EGCG with a Kd of 3.3 nM, and functional studies showed that EGCG inhibited the phosphorylation of vimentin at serine 50 and serine 55 by cell division cycle 2 (CDC2) with IC50 = 17 μM. The difference in effective concentrations is probably due to the nonspecific binding of EGCG to other proteins, which compete with the target protein. Vimentin knockdown by small interfering RNA in JB6 C141 cells resulted in a lower proliferation rate, and the cells became less responsive to inhibition by EGCG. IGF1R activation can induce cell proliferation and survival, as well as inhibit apoptosis, transformation, metastasis and angiogenesis in different types of cancer83. EGCG also inhibits IGF1R phosphorylation and increases expression of transforming growth factor-β2 (TGFβ2) in human colon cancer SW837 cells84, which is consistent with our observations in HRAS-transformed human bronchial epithelial 21BES cells85. The physical binding of EGCG to nucleic acids suggests that DNA and RNA can also be binding targets of green tea catechin86. However, the relevance of this proposed binding depends on whether the catechins can bind selectively to specific nucleic acid species in cancer or premalignant cells without affecting normal cells.

In general, if a biological effect of a compound can be observed in vitro at concentrations lower or similar to those observed in vivo, then the event can occur in vivo. Therefore, the discovery of the high-affinity EGCG-binding proteins discussed above is promising. The general applicability of these mechanisms for cancer prevention remains to be investigated.

Inhibition of enzyme activities

In collaboration with Z. Dong, we previously observed that EGCG, at concentrations of 5–20 μM, inhibited the phosphorylation of JNK (JUN N-terminal kinase), JUN, MEK1, MEK2, ERK1, ERK2 and ELK1 (Ets-like protein 1) in JB6 epidermal cell lines8789. This inhibition was associated with the inhibition of AP1 transcriptional activity or cell transformation. In vitro kinase assays suggested that EGCG inhibited MEK1 phosphorylation by decreasing its association with the kinase RAF1. Moreover, EGCG seems to inhibit the phosphorylation of ELK1 by competing with the binding site for ERK1 and ERK2 (REF 89). Inhibition of phosphorylation of JUN, ERK1 and ERK2 by EGCG or green tea polyphenols was also observed in lung carcinogenesis models30. Cyclin-dependent kinase 2 (CDK2) and CDK4 were also inhibited by 30 μM EGCG in MCF-7 breast cancer lines, and this was associated with cell cycle arrest in G0 and G1 (REF. 90).

EGCG has also been reported to inhibit the chymo-tryptic activity of 20S proteasomes91. Treatment of LNCaP prostate cancer cells with EGCG resulted in G0 and G1 cell cycle arrest92 and accumulation of p27 and inhibitor of nuclear factor-κB (IκB)91,93,94, both of which are targets for proteasomes. The difference of effective concentrations in cell-free systems (IC50 = 0.09–0.2 μM) and in cell lines (IC50 = 1–10 μM)91 suggests that EGCG may bind nonspecifically to proteins or other macromolecules in the cells and therefore lower the effective concentration of EGCG at the active site of the proteasome. In HT1080 human fibrosarcoma cells, EGCG and other catechins affect MMPs directly; the activity of secreted MMP2 and MMP9 was inhibited by EGCG with IC50 values of 8–13 μM in zymographic analysis95,96. EGCG also increased the expression of the tissue inhibitor of MMPs (TIMP1 and TIMP2) at lower concentrations (~1 μM), which provides an additional mechanism to suppress the activity of MMPs96. Additionally, EGCG inhibited the activation of pro-MMP2 by membrane-type MMP (also known as MMP14)97. These activities may contribute to the reported inhibition of metastasis and invasion following treatment of tumour-bearing mice with green tea or EGCG98. Further in vivo studies are needed to generate more direct evidence for this mechanism.

We reported that EGCG inhibited DNA methyltransferase (Ki = 7 μM) in KYSE 510 human oesophageal cancer cells and this resulted in the demethylation of the hypermethylated promoters of the tumour suppressor gene INK4A, retinoic acid receptor-β, and the DNA repair genes MLH1 and methylguanine methyltransferase; increases in gene expression were seen99. Reactivation of some of these genes was also observed in HT29 colon and PC3 prostate cancer cells. EGCG has also been reported to inhibit dihydrofolate reductase100, glucose-6-phosphate dehydrogenase101 and glyceraldehyde-3-phosphate dehydrogenase102. These enzyme inhibition results are biochemically interesting but it remains to be determined whether these activities can be demonstrated in vivo at a non-toxic dose of EGCG and how this enzyme inhibition might prevent cancer formation.

Inhibition of receptor-dependent signalling pathways and angiogenesis

Members of the epidermal growth factor receptor (Egfr) family are frequently overexpressed in human cancers and are associated with poor prognosis103. Many studies have demonstrated the inhibitory effects of EGCG on the Egfr signalling pathways14,104107. For example, it has been shown or suggested that EGCG can inhibit EGFR tyrosine kinase activity (IC50 =1–2 μM)104; inhibit the phosphorylation of EGFR, possibly by interfering with the binding of EGF to EGFR104; alter lipid organization in the plasma membrane (lipid rafts) and inhibit EGF binding to EGFR106; and induce internalization of EGFR into endosomes107. Inhibition of EGFR signalling has also been shown to decrease the production of VEGFA in cancer cells108. However, it is not known whether these actions of EGCG occur in vivo. The concept that EGCG may affect lipid rafts is interesting, although it remains to be demonstrated in vivo whether EGCG also alters the lipid rafts of normal cells and what concentration of EGCG is required to exert a desirable effect.

Deregulation of the hepatocyte growth factor (HGF)–HGFR pathway occurs in several types of human cancers and can lead to increased tumorigenesis and metastasis109. HGFR (a receptor tyrosine kinase also known as MET) and HGF have key roles in epithelial–mesenchymal transition, which is associated with tumour invasion110. It has been shown in MDA-MB-231 cells that the HGF-induced phosphorylation of HGFR and AKT1 was completely blocked by 0.6 μM EGCG, and that cell invasion was significantly decreased by 5 μM EGCG111. In a study with FaDu hypopharyngeal carcinoma cells, 1 μM EGCG prevented HCF-induced motility in an in vitro wound healing assay112.

Growth factors — such as VEGFA, fibroblast growth factor 2 (FGF2), IGF and EGF — serve as chemical stimuli to initiate angiogenesis, which provides nutrients for tumour growth. EGCG has been reported to decrease the RNA and peptide levels of VEGFA108,113. In addition, EGCG (0.5–10 μM) disrupted VEGFA-induced VEGFR2 dimerization and decreased the downstream PI3K activity in human umbilical vein endothelial cells114. We have previously observed the downregulation of VEGFA expression and suppression of angiogenesis by treatment with green tea (0.6% green tea solid in drinking fluid) in the NNK-induced lung tumorigenesis model28. Also, in a murine gastric tumour model, EGCG (1.5 mg per day per mouse, intraperitoneally for 28 days) suppressed VEGFA protein expression and tumour microvessel density115. In a recent report, EGCG (0.01% in drinking water) was shown to decrease FGF2 levels in lysates from intestinal tumours of ApcMin/+ mice116. Inhibition of FGF2 is also expected to contribute to an anti-angiogenic effect117.

Overview of cancer prevention mechanisms

As tea constituents, or even pure EGCG, have broad cancer-preventive effects in different animal models, it is likely that multiple molecular mechanisms, rather than a single receptor or molecular target, are involved. Even in a single experimental system, multiple molecular targets may still be involved. Among the mechanisms reviewed above and shown in FIG. 1, those with low effective concentrations in vitro are likely to occur in vivo. It is reasonable to suggest that EGCG initially binds to one or more of the target proteins, which may be transmembrane receptors, kinases or other enzymes. These actions may inhibit key signalling and metabolic pathways that are essential for the development of tumours, or may induce apoptosis of the premalignant or malignant cells. It remains a challenge to demonstrate the specific molecular events that are responsible for cancer prevention in animal models and humans. An interesting phenomenon that has been observed in different laboratories is the greater susceptibility of cancer cells to the inhibitory effect of EGCG and other chemopreventive agents than normal and non-transformed cells. A possible explanation for this phenomenon is the concept of oncogene addiction, as proposed by Weinstein and Joe118. According to this concept, the rapid growth of cancer cells depends on the aberrant activity or overexpression of a few oncogenes; if EGCG blocks the activity of one or two of these oncogenes, the cell growth would be severely inhibited and apoptosis would occur. Conversely, growth and survival of normal cells depends on the expression of many sets of pathways: when one or two of them are inhibited by EGCG, it would not significantly affect cell survival. The proposed cancer prevention mechanisms involving antioxidative and pro-oxidative actions and elimination of environmental carcinogens also need to be further investigated.

Concluding remarks

As discussed in this Review, the inhibitory activities of tea and tea polyphenols against carcinogenesis have been established in different animal models. Studies in cell lines have also demonstrated that tea polyphenols can affect a range of signalling and metabolic pathways. These molecular events may result in cancer cell growth inhibition, apoptosis and inhibition of invasion, angiogenesis and metastasis. On the basis of these results, we think that tea, which is readily available and widely consumed, has a high potential for application in the prevention of human cancer. Nevertheless, the cancer-preventive activity of tea has not been consistently observed in studies in humans. This may be due to the relatively low levels of tea consumption by some human populations (compared with animal studies) and the various confounding factors in epidemiological studies in different populations. The differences between in vitro and in vivo studies and the difficulties in extrapolating results from animal studies to humans also exist in cancer prevention studies with many other dietary constituents or food items. The lessons learned from studies on tea may be applicable to research on other cancer chemopreventive agents. Bioavailability is an issue with polyphenolic compounds. For agents that are not well absorbed systemically, direct contact with the digestive tract may be important for the cancer-preventive activity and this should also be applicable to the activities of EGCG and polyphenols in black tea. This concept is consistent with the results from studies on prevention of oral, oesophageal and colon cancer by black raspberry powder (which contains anthocyanins and ellagitannins) conducted by G. Stoner and colleagues119,120. More definitive information on the cancer-preventive activity of tea polyphenols will emerge from well-designed cohort studies and human intervention trials. Knowledge gained from the studies on the biological properties and activities of tea polyphenols reviewed in this article will be useful in the design of prospective studies and in the selection of the agent, dosage and biomarkers for intervention trials.


This work was supported by National Institutes of Health grants CA120915, CA122474 and CA133021.


Dietary recalls
A human dietary assessment procedure in which subjects are asked to recall their food consumptions over a certain time frame
Polyphenon E
A standard green tea polyphenol preparation containing 65% (−)-epigallocatechin-3-gallate
An inhibitor of 3-hydroxy-3-methyl-glutaryl CoA reductase and a commonly used cholesterol-lowering drug with the trade name Lipitor
A carcinogenic toxin produced by fungi that induces hepatic damage and leads to liver cancer
The concentration of a drug giving a 50% inhibition of the activity of a target enzyme
Lipid raft
A dynamic assembly of plasma membrane enriched in certain cholesterols, sphingolipids, saturated phospholipids and cell signalling proteins


1. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst. 1993;85:1038–1049. [PubMed]This is the first comprehensive review of the cancer preventive activities of tea.
2. Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer. 1998;31:151–159. [PubMed]
3. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 2002;42:25–54. [PubMed]
4. Hou Z, Lambert JD, Chin KV, Yang CS. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res. 2004;555:3–19. [PubMed]
5. Lambert JD, Hong J, Yang GY, Liao J, Yang CS. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr. 2005;81:284S–291S. [PubMed]
6. Clark J, You M. Chemoprevention of lung cancer by tea. Mol Nutr Food Res. 2006;50:144–151. [PubMed]
7. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res. 2006;66:2500–2505. [PubMed]
8. Wu AH, Yu MC. Tea, hormone-related cancers and endogenous hormone levels. Mol Nutr Food Res. 2006;50:160–169. [PubMed]
9. Yang CS, et al. Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res. 2006;50:170–175. [PubMed]
10. Ju J, Lu G, Lambert JD, Yang CS. Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol. 2007;17:395–402. [PMC free article] [PubMed]
11. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997;37:693–704. [PubMed]This is a comprehensive review of the composition of different types of tea and the chemistry of tea constituents.
12. Valcic S, Burr JA, Timmermann BN, Liebler DC. Antioxidant chemistry of green tea catechins. New oxidation products of (−)-epigallocatechin gallate and (−)-epigallocatechin from their reactions with peroxyl radicals. Chem Res Toxicol. 2000;13:801–810. [PubMed]
13. Sang SM, et al. Theadibenzotropolone A, a new type pigment from enzymatic oxidation of (−)-epicatechin and (−)-epigallocatechin gallate and characterized from black tea using LC/MS/MS. Tetrahedron Lett. 2002;43:7129–7133.
14. Hou Z, et al. Mechanism of action of (−)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res. 2005;65:8049–8056. [PubMed]
15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26. [PubMed]
16. Lee MJ, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (−)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev. 2002;11:1025–1032. [PubMed]
17. Chow HH, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003;9:3312–3319. [PubMed]This article reports the detailed pharmacokinetics and safety of green tea polyphenols in humans.
18. Chow HH, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res. 2005;11:4627–4633. [PubMed]
19. Chen L, Lee MJ, Li H, Yang CS. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos. 1997;25:1045–1050. [PubMed]
20. Lambert JD, et al. Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues. Drug Metab Dispos. 2006;34:8–11. [PubMed]
21. Yang CS, Sang S, Lambert JD, Lee MJ. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res. 2008;52(Suppl 1):139–151. [PubMed]
22. Wang ZY, et al. Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosamino)-1 -(3-pyridyl)-1 -butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res. 1992;52:1943–1947. [PubMed]This is the first publication demonstrating the inhibition of lung carcinogenesis by green and black tea.
23. Xu Y, Ho CT, Amin SG, Han C, Chung FL. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res. 1992;52:3875–3879. [PubMed]This is the first demonstration of the inhibition of lung tumorigenesis by EGCG and caffeine.
24. Yang GY, et al. Black tea constituents, theaflavins, inhibit 4-(methylnitrosamino)-1 -(3-pyridyl)-1 -butanone (NNK)-induced lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18:2361–2365. [PubMed]
25. Chung FL, et al. Inhibition of lung carcinogenesis by black tea in Fischer rats treated with a tobacco-specific carcinogen: caffeine as an important constituent. Cancer Res. 1998;58:4096–4101. [PubMed]
26. Mimoto J, et al. (−)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. Carcinogenesis. 2000;21:915–919. [PubMed]
27. Zhang Z, et al. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res. 2000;60:901–907. [PubMed]
28. Liao J, et al. Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in A/J mice by oral administration of green tea. Nutr Cancer. 2004;48:44–53. [PubMed]
29. Schuller HM, Porter B, Riechert A, Walker K, Schmoyer R. Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers. Lung Cancer. 2004;45:11–18. [PubMed]
30. Lu G, et al. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1 -(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006;66:11494–11501. [PubMed]
31. Landau JM, Wang ZY, Yang GY, Ding W, Yang CS. Inhibition of spontaneous formation of lung tumors and rhabdomyosarcomas in A/J mice by black and green tea. Carcinogenesis. 1998;19:501–507. [PubMed]
32. Sazuka M, Murakami S, Isemura M, Satoh K, Nukiwa T. Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Cancer Lett. 1995;98:27–31. [PubMed]
33. Lu G, et al. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res. 2008;14:4981–4988. [PubMed]
34. Lu Y, et al. A gene expression signature that can predict green tea exposure and chemopreventive efficacy of lung cancer in mice. Cancer Res. 2006;66:1956–1963. [PubMed]
35. Li N, et al. Inhibition of 7,12-dimethylbenz[a] anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis. 2002;23:1307–1313. [PubMed]
36. Wang ZY, et al. Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis. 1995;16:2143–2148. [PubMed]
37. Yamane T, et al. Inhibition of N-methyl-N′-nitro-N-nitrosoguanidine-induced carcinogenesis by (−)-epigallocatechin gallate in the rat glandular stomach. Cancer Res. 1995;55:2081–2084. [PubMed]
38. Murugan RS, et al. Modulatory effects of black tea polyphenols on oxidant–antioxidant profile and expression of proliferation, apoptosis, and angiogenesis-associated proteins in the rat forestomach carcinogenesis model. J Gastroenterol. 2007;42:352–361. [PubMed]
39. Ju J, et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (−)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res. 2005;65:10623–10631. [PubMed]
40. Hao X, et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by green tea polyphenols (polyphenon E) and individual catechins. Nutr Cancer. 2007;59:62–69. [PubMed]
41. Xiao H, et al. Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis. 2008;29:113–119. [PubMed]
42. Carter O, et al. Comparison of white tea, green tea, epigallocatechin-3-gallate, and caffeine as inhibitors of PhIP-induced colonic aberrant crypts. Nutr: Cancer. 2007;58:60–65. [PubMed]
43. Wang R, et al. Protective versus promotional effects of white tea and caffeine on PhIP-induced tumorigenesis and β-catenin expression in the rat. Carcinogenesis. 2008;29:834–839. [PMC free article] [PubMed]
44. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 1995;96:239–243. [PubMed]
45. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA. 2001;98:10350–10355. [PubMed]This is the first demonstration of the inhibition of prostate carcinogenesis in a mouse model by green tea polyphenols and related mechanisms.
46. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. CancerRes. 2004;64:8715–8722. [PubMed]
47. Gao YT, et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer lnst. 1994;86:855–858. [PubMed]
48. Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: cancer preventive beverage and/or drug. Cancer Lett. 2002;188:9–13. [PubMed]
49. Zhang M, Holman CD, Huang JP, Xie X. Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis. 2007;28:1074–1078. [PubMed]
50. Sun CL, et al. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis. 2002;23:1497–1503. [PubMed]
51. Yuan JM, Gao YT, Yang CS, Yu MC. Urinary biomarkers of tea polyphenols and risk of colorectal cancer in the Shanghai Cohort Study. Int J Cancer. 2007;120:1344–1350. [PubMed]
52. Sasazuki S, Inoue M, Miura T, Iwasaki M, Tsugane S. Plasma tea polyphenols and gastric cancer risk: a case-control study nested in a large population-based prospective study in Japan. Cancer Epidemiol Biomarkers Prev. 2008;17:343–351. [PubMed]
53. Wu AH, Yu MC, Tseng CC, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. Int J Cancer. 2003;106:574–579. [PubMed]
54. Wu AH, Tseng CC, Van Den Berg D, Yu MC. Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res. 2003;63:7526–7529. [PubMed]
55. Bonner MR, et al. Green tea consumption, genetic susceptibility, PAH-rich smoky coal, and the risk of lung cancer. Mutat Res. 2005;582:53–60. [PubMed]
56. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med. 1999;220:218–224. [PubMed]
57. Ahn WS, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev. 2003;12:383–390. [PubMed]
58. Bettuzzi S, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66:1234–1240. [PubMed]This is the first demonstration that green tea polyphenols prevented the progression of high-grade PIN to prostate cancer.
59. Shimizu M, et al. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 2008;17:3020–3025. [PubMed]
60. Conney AH, et al. Stimulatory effect of oral administration of tea, coffee or caffeine on UVB-induced apoptosis in the epidermis of SKH-1 mice. Toxicol Appl Pharmacol. 2007;224:209–213. [PubMed]
61. Srividhya R, Jyothilakshmi V, Arulmathi K, Senthilkumaran V, Kalaiselvi P. Attenuation of senescence-induced oxidative exacerbations in aged rat brain by (−)-epigallocatechin-3-gallate. Int J Dev Neurosci. 2008;26:217–223. [PubMed]
62. Senthil Kumaran V, Arulmathi K, Srividhya R, Kalaiselvi P. Repletion of antioxidant status by EGCG and retardation of oxidative damage induced macromolecular anomalies in aged rats. Exp Gerontol. 2008;43:176–183. [PubMed]
63. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr. 2003;43:89–143. [PubMed]
64. Inami S, et al. Tea catechin consumption reduces circulating oxidized low-density lipoprotein. Int Heart J. 2007;48:725–732. [PubMed]
65. Hsu SP, et al. Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines. Am J Clin Nutr. 2007;86:1539–1547. [PubMed]
66. Hakim IA, et al. Effect of increased tea consumption on oxidative DNA damage among smokers: a randomized controlled study. J Nutr. 2003;133:3303S–3309S. [PubMed]
67. Schwartz JL, Baker V, Larios E, Chung FL. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res. 2005;49:43–51. [PubMed]
68. Yang GY, Liao J, Kim K, Yurkow EJ, Yang CS. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 1998;19:611–616. [PubMed]
69. Na HK, Surh YJ. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol. 2008;46:1271–1278. [PubMed]
70. Shen G, et al. Comparison of (−)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/56J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm Res. 2005;22:1805–1820. [PubMed]
71. Chow HH, et al. Modulation of human glutathione S-transferases by polyphenon E intervention. Cancer Epidemiol Biomarkers Prev. 2007;16:1662–1666. [PubMed]
72. Tang L, et al. Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention. Carcinogenesis. 2008;29:411–417. [PubMed]
73. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis) Ann Intern Med. 2006;144:68–71. [PubMed]
74. Lambert JD, Sang S, Yang CS. Possible controversy over dietary polyphenols: benefits vs risks. Chem Res Toxicol. 2007;20:583–585. [PubMed]This article discusses possible benefits and risks of taking green tea extract as a dietary supplement.
75. Tachibana H, Koga K, Fujimura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nature Struct Moi Biol. 2004;11:380–381. [PubMed]This is the first report of the identification of EGCG targets in a cell line.
76. Umeda D, Yano S, Yamada K, Tachibana H. Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J Biol Chem. 2008;283:3050–3058. [PubMed]
77. Leone M, et al. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. CancerRes. 2003;63:8118–8121. [PubMed]
78. Ermakova S, et al. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem. 2005;280:16882–16890. [PubMed]This is the first report of the identification of an EGCG target protein by affinity chromatography and molecular studies.
79. Li M, et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev. 2007;16:598–605. [PubMed]
80. He Z, et al. Fyn is a novel target of (−)-epigallocatechin gallate in the inhibition of JB6 C141 cell transformation. Moi Carcinog. 2008;47:172–183. [PMC free article] [PubMed]
81. Ermakova SP, et al. (−)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006;66:9260–9269. [PubMed]
82. Shim JH, et al. (−)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J Biol Chem. 2008;283:28370–28379. [PMC free article] [PubMed]
83. Mitsiades CS, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221–230. [PubMed]
84. Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein IB. EGCG inhibits activation of the insulinlike growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun. 2005;334:947–953. [PubMed]
85. Vittal R, et al. Gene expression changes induced by green tea polyphenol (−)-epigallocatechin-3-gallate in human bronchial epithelial 21 BES cells analyzed by DNA microarray. Moi Cancer Ther. 2004;3:1091–1099. [PubMed]
86. Kuzuhara T, Sei Y, Yamaguchi K, Suganuma M, Fujiki H. DNA and RNA as new binding targets of green tea catechins. J Biol Chem. 2006;281:17446–17456. [PubMed]
87. Dong Z, Ma W, Huang C, Yang CS. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (−)-epigallocatechin gallate, and theaflavins. Cancer Res. 1997;57:4414–4419. [PubMed]
88. Chung JY, Huang C, Meng X, Dong Z, Yang CS. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. 1999;59:4610–4617. [PubMed]
89. Chung JY, Park JO, Phyu H, Dong Z, Yang CS. Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (−)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J. 2001;15:2022–2024. [PubMed]
90. Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (−)-epigallocatechin-3-gallate. J Cell Biochem. 1999;75:1–12. [PubMed]
91. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276:13322–13330. [PubMed]
92. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (−)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol. 2000;164:82–90. [PubMed]
93. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (−)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys. 2003;410:177–185. [PubMed]
94. Smith DM, et al. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med. 2002;8:382–392. [PMC free article] [PubMed]
95. Garbisa S, et al. Tumor invasion: molecular shears blunted by green tea. Nature Med. 1999;5:1216. [PubMed]
96. Garbisa S, et al. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer. 2001;91:822–832. [PubMed]
97. Annabi B, et al. Green tea polyphenol (−)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT 1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta. 2002;1542:209–220. [PubMed]
98. Taniguchi S, et al. Effect of (−)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett. 1992;65:51–54. [PubMed]
99. Fang MZ, et al. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyl transferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563–7570. [PubMed]
100. Navarro-Peran E, et al. The antifolate activity of tea catechins. Cancer Res. 2005;65:2059–2064. [PubMed]
101. Shin ES, et al. Catechin gallates are NADP + -competitive inhibitors of glucose-6-phosphate dehydrogenase and other enzymes that employ NADP+ as a coenzyme. Bioorg Med Chem. 2008;16:3580–3586. [PubMed]
102. Ishii T, et al. Covalent modification of proteins by green tea polyphenol (−)-epigallocatechin-3-gallate through autoxidation. Free Radio Biol Med. 2008;45:1384–1394. [PubMed]
103. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer. 2006;94:184–188. [PMC free article] [PubMed]
104. Liang YC, Lin-shiau SY, Chen CF, Lin JK. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem. 1997;67:55–65. [PubMed]
105. Shimizu M, et al. (−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res. 2005;11:2735–2746. [PubMed]
106. Adachi S, et al. The inhibitory effect of (−)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res. 2007;67:6493–6501. [PubMed]
107. Adachi S, et al. (−)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986–1993. [PubMed]
108. Masuda M, et al. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol. 2002;2:350–359. [PubMed]
109. Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene. 2007;26:1276–1285. [PubMed]
110. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nature Rev Mol Cell Biol. 2003;4:915–925. [PubMed]
111. Bigelow RL, Cardelli JA. The green tea catechins, (−)-Epigallocatechin-3-gallate (EGCG) and (−)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene. 2006;25:1922–1930. [PubMed]
112. Lim YC, et al. (−)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 2008;271:140–152. [PubMed]
113. Sartippour MR, et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr. 2002;132:2307–2311. [PubMed]
114. Rodriguez SK, et al. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer. 2006;118:1635–1644. [PubMed]
115. Zhu BH, et al. (−)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol. 2007;13:1162–1169. [PubMed]
116. Sukhthankar M, et al. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer. Gastroenterology. 2008;134:1972–1980. [PMC free article] [PubMed]
117. Ciardiello F, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7:1459–1465. [PubMed]
118. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077–3080. discussion 3080. [PubMed]
119. Stoner GD, et al. Cancer prevention with freeze-dried berries and berry components. Semin Cancer Biol. 2007;17:403–410. [PMC free article] [PubMed]
120. Shumway BS, et al. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin Cancer Res. 2008;14:2421–2430. [PMC free article] [PubMed]